Regeneron forecasts strong Eylea sales; shares rise

(Reuters) – Regeneron Pharmaceuticals Inc forecast U.S. sales of eye drug Eylea to reach $1.7-$1.8 billion in 2014 as it expects the drug to win approval for newer uses, sending its shares up 3…

    

Leave a Reply

Your email address will not be published.